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ABSTRACT 
Triclisia subcordata Oliv (Menispermeaceae) is a medicinal plant traditionally used for 
the treatment of various diseases in West Africa. The ethanol extract of T. subcordata 
and its fractions were screened for in vitro anti-ovarian cancer activities using the 
Sulforhodamine B assay. The crude alkaloids showed the strongest activity in cell 
growth assays on A2780 and Ovcar-8 cell lines (IC
50
 < 2.4 µg/mL). A 
bisbenzylisoquinoline alkaloid-cycleanine was isolated using HPLC and identified by 
MS and NMR analyses. The IC
50
 values of cycleanine and tetrandrine (an alkaloid 
previously reported from this plant) ranged from 7 to 14 µM on A2780, Ovcar-8, Ovcar-
4 and Igrov-1 ovarian cancer cell lines. The IC
50
 of cycleanine on human normal 
ovarian surface epithelial cells was 35 ± 1 µM hinting at modest selectivity towards 
cancer cells. Both cycleanine and tetrandrine caused apoptosis as shown by activation of 
caspases 3/7 and cleavage of poly (ADP) ribose polymerase (PARP) to form PARP-1. 
Flow cytometry analyses showed that the percentages of apoptotic cells and cells in 
subG1 phase increased after exposure of cycleanine and tetrandrine to Ovcar-8 cells for 
48h compared to control.  Cycleanine, like its isomer – tetrandrine isolated from 
Triclisia subcordata, could be a potential new anti-ovarian cancer agent acting through 
the apoptosis pathway.                  
Keywords: Triclisia subcordata, cycleanine, tetrandrine, anti-proliferation, apoptosis, 
ovarian cancer   
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INTRODUCTION 
Ovarian cancer continues to be one of the main causes of death in all gynecologic 
malignancies (Siegel et al., 2013). Natural products remain an important source of 
clinically approved anti-cancer drugs (e.g. paclitaxel from yew tree) (Cragg et al., 2009; 
Li et al., 2015) suggesting they may provide a source of novel treatments for ovarian 
cancer. The bisbenzylisoquinoline (BBIQ) alkaloids are a large group of natural 
products occurring in many plant species in Families like Menispermeaceae, 
Ranunculaceae, Annonaceae, and Monimiaceae (Schiff, 1997). These alkaloids are 
made up of two isoquinonines (“head part”) linked to two benzyl moieties (“tail part”) 
through two types of linkage such as head-to-tail (e.g. cycleanine) and head-to-head 
(e.g. tetrandrine) (Fig. S1). The BBIQ alkaloids possess a range of biological activities 
including anticancer (Sun and Wink, 2014; Wang et al., 2010), inhibition of histamine 
release (Nakamura et al., 1992), antiplasmodial (Angerhofer et al., 1999), and 
antileishmanial and antitrypanosomal effects (del Rayo Camacho et al., 2002).  
Triclisia subcordata Oliv (Menispermeaceae) has been reported to have anti-ulcer 
(Asuzu and Anaga, 1996), antihistamine and antimicrobial activities (Abo et al., 2011). 
Early phytochemical studies in the 1970s revealed the presence of only three BBIQ 
alkaloids: tricordatine (Tackie et al., 1973), fangchinoline (Tackie et al., 1974), and 
tetrandrine (Dwuma-Badu et al., 1975) from this plant species. However, no anti-cancer 
activity of extracts of T. subcordata constituent alkaloids or further phytochemical 
study has been reported. Therefore, in continuation of our search for anticancer 
compounds from medicinal plants (Johnson-Ajinwo et al., 2015; Li et al., 2013; Li et 
al., 2015), this study aimed to evaluate the in vitro anti-ovarian cancer activities of the 
crude extracts and pure compounds of T. subcordata and bioassay-guided fractionation 
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was used to isolate the bioactive compound. Furthermore, the cytotoxic effects and 
possible signalling pathways of cycleanine and tetrandrine involved in their cytotoxity 
on A2780, Ovcar-8, Ovcar-4 and Igrov-1 ovarian cancer cell lines were investigated. 
 
EXPERIMENTAL 
 
Plant Materials  
 
The plant materials of Triclisia subcordata were collected in 2012 from Imo state, 
Nigeria and identified by a taxonomist, H.D Onyeachusim. The voucher specimen 
(Voucher number UUH 1817) was deposited at the herbarium of University of Uyo, 
Akwa Ibom state, Nigeria.  The root bark of the plant part was cut into pieces, air-dried 
and pulverized. 
 
Extraction and fractionation 
 
The powdered root bark of T. subcordata (250 g) was extracted with 1 L of 50 % 
ethanol by Soxhlet apparatus. The extract was concentrated to dryness using rotary 
evaporator.  The total T. subcordata extract (TSS) was subjected to further fractionation 
according to a published procedure (Kikueta et al., 2013) to yield the chloroform 
fraction containing enriched alkaloid (TSS1), the aqueous extract (TSS2) and the 
aqueous methanol fraction (TSS3) (Fig. S2). 
 
Isolation of cycleanine 
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The TSS1 (273 mg), which showed most cytotoxic activity, was subjected to silica gel 
chromatography eluting with CHCl3 with increasing amount of MeOH to give 40 
fractions. The eluted fractions were tested, identified and combined as guided by 
Dragendorff’s reagent test, thin layer chromatography and UV detector at 254 nm and 
365 nm wavelength. The combined fractions were concentrated in vacuum with rotary 
evaporator. Cycleanine (145 mg) was recrystallized from 1-4
th
 fraction (TSS1.1). 
Fractions 5-8were combined as TSS1.2 and further purified by high performance liquid 
chromatography (HPLC). Purification of TSS1.2 (27.8 mg) was carried out using HPLC 
on an Agilent 1220 LC system (USA). UV detector was set at 254 nm wavelength.  The 
mobile phase was a mixture of 0.1 % trifluoroacetic acid (TFA) (A) and 80% 
Acetonitrile containing 0.1 % TFA (B). The composition of the mobile phase was rising 
from 10 % to 70% B over a period of 25 min and kept at 100 % B for 6 min on a semi-
preparative HPLC column (Phenomenex, UK; Jupiter C18 reverse phase, 300 A, 5 μm 
particle size, 9.4 × 250 mm) at a flow rate of 4 mL/min. Eluted fractions at different 
retention time were collected and freeze-dried on a lyophylizer. For analysis of the 
purity of the isolated alkaloids, a gradient from 10 % B to 70 % B over a period of 25 
min and 100 % B for 6 min was applied on an analytical HPLC column (Phenomenex, 
UK; Jupiter C18 reverse phase, 300 A, 5 μm particle size, 4.6 × 250 mm) at a flow rate 
of 1 mL/min.   
 
Characterization of cycleanine and TFA salt of cycleanine 
 
Cycleanine, white powder (purity > 98%), 
1
H and 
13
C NMR (CDCl3), see Table S1 and 
S2; LC-ESI-MS, m/z: 623.3118 [M + H]
+
; 312.1610 [M + 2H]
2+
.  TFA salt of 
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cycleanine, white powder. 
1
H and 
13
C NMR (CDCl3), see Table S1 and S2; LC-ESI-
MS, m/z: 623.3074 [M + H]
+
; 312.1579 [M + 2H]
2+
.  
 
Cell culture 
The human ovarian cancer cell lines (Ovcar-8, Ovcar-4, A2780 and Igrov-1) and normal 
human ovarian surface epithelial (OSE) cells were cultured in RPMI 1640 medium 
supplemented with 10% FBS, penicillin-streptomycin (50 U/ml) and glutamine (2 mM). 
 
Cell proliferation assay 
The Sulforhodamine B (SRB) assay (Johnson-Ajinwo et al., 2015) was used to evaluate 
the effects of the plant extracts and pure compounds on the growth of ovarian cancer 
cell lines (A2780, Ovcar-8, Ovcar-4, Igrov-1) and human normal OSE cells.  2000 cells 
(A2780, Ovcar-8), and 5000 (Ovcar-4, Igrov-1, or OSE) cells were seeded in 80 µl of 
growth medium in each well of a 96-well plate. After 24 hours 20 µl of plant extracts 
dissolved in DMSO (final concentration 0.2%) or pure compounds were added. After 72 
hours the medium was decanted and the cells were fixed with 10% trichloroacetic acid 
on ice for 30 min before drying. The cells were stained with 0.4% SRB in 1% acetic 
acid for 30 min, washed with 1% acetic acid and dried. Then, 200 µL of Tris-base (10 
mM) were added to the dried plates and shaken for 5 min to solubilise the SRB dye. The 
absorbance at 540 nm was measured using a spectroscopic plate reader. The data was 
analysed by non-linear regression using the GraphPad PRISM 6 software to fit a 4 
parameter sigmoidal concentration-response curve.  
Cell counting 
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The viability of A2780 cancer cells was measured using trypan blue exclusion method 
(Invitrogen) before seeding cells and after drug treatment of the cells. The cells (A2780, 
Ovcar-8, Ovcar-4, or Igrov-1) (200, 000 cells/well) were seeded into 6 well plates, and 
medium (control), carboplatin, cycleanine or tetrandrine (20 µM) were administered to 
the cells after 24hr incubation. Then cell viability was determined using 
haemocytometer and trypan blue exclusion after 48h treatment. Briefly, 20 μL cells 
culture were collected after trypsinization and mixed with and equal volume of 0.4% 
trypan blue thoroughly. Then 20 μL of the suspension mixture was analysed with a 
Countess™ Automated Cell Counter (Life Technologies) to determine cell viability. 
 
Caspase – Glo 3/7 activity assay 
 
The effect of cycleanine and tetrandrine on the caspase-3/7 activities was carried out 
using assay kits Caspase-Glo 3/7 (Promega Corp., Madison, WI, USA) on a 96-well 
microplate as described previously with little modification (Robinson et al., 2013). 
Briefly, A2780 and Ovcar-8 (2000 cells/well), and Igrov-1 and Ovcar-4 (5000 
cells/well) cells were incubated in 80 μL growth medium in a 96-well plate for 24 
hours. Cells were then supplemented with growth medium (control), carboplatin, 
cycleanine or tetrandrine (final concentration 20 μM) for 48 hours.  Before adding 
caspase agents, the morphological changes were observed and the images were captured 
under an inverted light microscope. Then, 100 μL of the culture was treated with 25 μL 
caspase-Glo 3/7 reagent and incubated at room temperature on a Rocker (Gyro shaker) 
for 30 minutes, protected from light.  The reading was measured at 570 nm by Multi-
Mode Microplate Reader BioTEK Synergy 2 (USA). 
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Western blot assay for PARP cleavage 
To evaluate apoptosis, 200,000
 
Ovcar-8 cells /ml were seeded in a 6-well plate and were 
treated with cycleanine, tetrandrine, carboplatin (20 µM) or medium for 48 h. Cells 
were collected by trypsinization, lysed, protein concentration determined by the 
bicinchoninic acid assay. Equal amounts of proteins (10 g) from total cellular extracts 
were resolved on 4-20% Tris-Glycine polyacrylamide gradient gel (Nusep) with hepes 
running buffer (100 mM hepes, 100 mM Tris and 1% sodium dodecyl sulphate). After 
electrophoresis, the proteins on the gel were transferred to PVDF membrane. The 
membrane was then incubated with Tris buffered saline with tween buffer (50 mM Tris 
hydrochloride (Tris HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) containing 5% 
skimmed milk powder for 1.0 hour with gentle rocking on a Stuart Scientific Platform 
Shaker STR6 at room temperature.  The membrane was then probed with  antibodies 
against poly (ADP) ribose polymerase (PARP) (Cell Signaling Technology Inc., USA) 
(1:1000) for 16 hours at 4°C overnight or  glyceraldehde-3-phosphate dehydrogenase 
(GAPDH) from mouse (Millipore, USA) (1:5000) for 1 hour at room temperature. 
Protein were visualised using UptiLight HRP chemiluminescent substrate (Uptima) on a 
FluorChem M Imager,  quantified by using AlphaView SA software (Protein Simple) 
and then normalised to the loading control, GAPDH.  
Apoptosis assay with flow cytometry analysis 
0.5 ml of Ovcar-8 cells (300,000 cells/ml) were seeded in 12 well plates for 24h, and exposed to 
medium as control, carboplatin, cycleanine and tetrandrine (20 µM). After incubation for 48 h, the 
cells were washed with PBS, trypinsized and stained with fluorescein isothycanate (FITC)-
conjugated annexin V using Annexin V-FITC kit (Miltenyi Biotec, Germany) and popidium 
iodide (PI) following the manufacturer’s protocol. Apoptotic and live cells were measured using 
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a Beckman Coulter Cytomics 500 flow cytometer with CXP software (High Wycombe 
UK). Flow cytometry data was analysed using Flowing Software (Perttu Terho, Turku 
Centre for Biotechnology, University of Turku, Finland). The percentage of early and later 
apoptotic, and live cells in three independent experiments were statistically analyzed using 
GraphPad Prism 6 software.  
Cell cycle analysis by flow cytometry 
Ovcar-8 1 × 10
6
 cells/well seeded in a 6-well plates were treated with cycleanine, 
tetrandrine, carboplatin (20 µM), and medium (control) for 48 hr. The adherent cells 
were trypinized and washed with PBS. The cells were then fixed with 70% ethanol in 
cold PBS, and incubated at 4
o
C for 24 hr. The fixed cells were centrifuged at 200 g for 
10 mins and the cell pellets were washed twice with PBS. Cells were suspended in PBS 
containing propidium iodide (PI) (50 µg/mL), Triton X-100 (0.1%, v/v), and DNase-
free RNase (1 µg/mL). DNA contents were determined by flow cytometry and analysed 
by Flowing software.  
RESULTS 
  
The extraction and fractionation of T. subcordata (Fig. S2) yielded the total crude 
extract (TSS), the total alkaloid (TSS1), the aqueous extract (TSS2) and the aqueous 
methanol fraction (TSS3). Both TSS1 and TSS3 showed positive Dragendorff’s tests, 
which indicated the presence of alkaloids in these fractions. All of these fractions 
inhibited the growth of Ovcar-8 and A2780 ovarian cancer cells (Table 1 and Fig. 1A), 
but the most potent activity was exhibited by the alkaloid enriched TSS1. TSS1 also 
showed some selectivity for the cancer cells because the growth of normal OSE was 
inhibited with almost 10-fold lower potency (Table 1).  
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Bioassay-guided fractionation of TSS1 resulted in isolation of a single, highly pure 
alkaloid using silica gel chromatography and/or HPLC (Fig. S3), which was identified 
on the basis of spectroscopic data including LC-MS, 
1
H NMR, and 
13
C NMR (Table S1 
and S2) as the bisbenzylisoquinoline alkaloid cycleanine (Fig. S1). Cycleanine was also 
isolated as a TFA salt form when using HPLC where the solvent system contained 0.1 
% TFA. 
1
H NMR and 
13
C NMR of the TFA salt of cycleanine showed slight difference 
from those of cycleanine (Table S1 and S2).  
 
Cell growth assays 
 
The potency of cycleanine and tetrandrine in cell growth assay was investigated. They 
both inhibited the growth of 4 ovarian cancer cell lines with microMolar potencies (Fig. 
1B and Table 2). The selective index (SI) of cycleanine ranged between 3 and 5.   
Consistent with the preliminary evidence for moderate selectivity of TSS1 for cancer 
cells, cycleanine showed modestly less potency against human OSE cells than the 
cancer cells.    
 
Cytotoxicity 
 
The trypan blue exclusion method was employed to distinguish cytotoxic and cytostatic 
effects. The viability of A2780, Ovcar-8, Igrov-1 and Ovcar-4 cells was reduced 
substantially by cycleanine and tetrandrine, as well as by the positive control 
carboplatin, when the four cancer cell lines were exposed to the two alkaloids for 48 h 
(Fig. 1C). 
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Apoptosis 
 
To evaluate whether the decrease in viability caused by cycleanine was due to 
apoptosis, the activation of caspase 3/7 activity by cycleanine and tetrandrine was 
evaluated.  Increased level of caspase activity in Ovcar-8, A2780 and Igrov-1 cells were 
observed (Fig. 2). Cycleanine increased caspase activity comparably to carboplatin, 
whereas tetrandrine augmented caspase activity noticeably more, up to 8 fold (Fig. 2). 
Morphological alterations of Ovcar-8 cells treated with carboplatin, cycleanine and 
tetrandrine were also consistent with apoptosis including membrane blebbing and cell 
detachment (Fig. S4).   
To confirm the cells underwent apoptosis, PARP cleavage, a marker of apoptosis, was 
assessed by immunoblotting. Exposure of Ovcar-8 cells to cycleanine, tetrandrine, or 
carboplatin resulted in significant PARP cleavage (Fig. 3). 
To further quantify the percentage of apoptotic cells after treatment of these alkaloids, 
the cells were stained by Annexin V and PI and analysed by flow cytometry (Fig. 4). 
Carboplatin, cycleanine and tetrandrine treatment after 48 h caused significant increase 
of the population of both early and late apoptotic cells compared to the control cells.  
  
Cell cycle analysis 
The effects of cycleanine, tetrandrine, and carboplatin  on cell cycle distribution of 
Ovcar-8 cells are shown in Fig. 5. The percentage of Ovcar-8 cells in subG1 increased 
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after exposure to cycleanine, tetrandrine, and carboplatin to for 48h compared to 
control, consistent with apoptosis (Fig. 5).   
 
DISCUSSION 
 
Cycleanine has been isolated from many other plant species of the Menispermaceae 
family (Schiff, 1997). Cycleanine was shown to increase the intracelluar doxorubicin 
accumulation in the resistant MCF-7/Adr cell lines (Tian and Pan, 1997).  
Tetrandrine is also a common BBIQ alkaloid found in different plants as well as in T. 
subcordata (Dwuma-Badu et al., 1975). It showed various biological activities 
including anticancer (Chen, 2002), anti-allergic, anti-inflammatory, anti-malarial, and 
cardiovascular effects (Schiff, 1997). Tetrandrine inhibited the growth of various types 
of cancer cells (Chen, 2002; He et al., 2011; Xu et al., 2011) and could reverse 
multidrug resistance by inhibiting P-glycoprotein activity (Sun and Wink, 2014).  
Here, cycleanine has been isolated and characterized from T. subcordata, as part of 
novel contribution to knowledge. The analytical data (ESI-MS and NMR) were 
consistent with literature data for cycleanine (Kanyinda et al., 1997). The change of 
1
H 
NMR signals of cycleanine by TFA was observed and such features were often found 
for the other alkaloids (Verpoorte, 1986).  Furthermore, we showed that both a head-to-
tail BBIQ cycleanine (including TFA salt of cylcleanine) and a head-to-head BBIQ 
tetrandrine which is an isomer of cycleanine and was previously isolated from T. 
subcordata (Fig. S1) showed potent anti-ovarian cancer activities. While such a 
structural difference in BBIQ alkaloids was key to the inhibition of histamine release as 
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only the head-to-tail BBIQ such as tetrandrine showed the inhibition (Nakamura et al., 
1992).  
The induction of apoptosis by tetrandrine was observed previously in human lung 
carcinoma (Lee et al., 2002), bladder cancer (Li et al., 2011), colorectal cancer (He et 
al., 2011), gallbladder carcinoma (Zhu et al., 2014), and prostate cancer cells (Liu et al., 
2015). The combination of tetrandrine and cisplatin caused enhanced cytotoxicity 
through apoptosis  as well as redistribution of the cell cycle in ovarian cancer cells in 
vitro and vivo (Zhang et al., 2011). To confirm that these two types of BBIQ alkaloids 
(cycleanine and tetrandrine) could induce apoptosis in ovarian cancer cell lines, two 
markers of apoptosis including caspases 3/7 and cleavage of PARP to its 89 kDa 
fragment were measured. Cycleanine and tetrandrine significantly increased caspase 3/7 
activity in all cell lines tested, indicating the induction of apoptotic cell death (Fig. 2). 
The apoptotic activity was further confirmed by the detection of the PARP-1 fragment 
in cycleanine and tetrandrine-treated Ovcar-8 cells using immunoblotting assay (Fig. 3). 
The percentage of the apoptotic cells caused by tetrandrine is greater than those by 
cycleanine and carboplatin (Fig. 4). Tetrandrine increased population of both apoptotic 
sub-G1 and G1 phase in the lung cancer cells (Lee et al., 2002). The increase of cell 
fraction of sub-G1 by tetrandrine was also observed in ovarian cancer cells in this study 
indicating the induction of apoptosis because such sub-G1 peak is often regarded as a 
characteristic indicator of apoptosis (Kajstura et al., 2007). Interestingly, cycleanine was 
shown in this studay to cause apoptosis in cancer cells similar as tetrandrine but with 
less potency (Fig. 2, 4, 5). 
In this study, the extracts and BBIQ alkaloids of T. subcordata were demonstrated to 
exert significant in vitro anti-ovarian cancer activities, which provided a scientific basis 
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for future potential use of this plant for the treatment of ovarian cancer. Importantly, 
cycleanine showed a modest selectivity towards ovarian cancer cells over normal cells 
via apoptosis, which may be used as a hit to modify its structure by semi-synthesis in 
order to improve its anti-cancer activity. To be approved as anticancer drugs, in vivo 
activities of these alkaloids and analogues must be evaluated. This work is ongoing in 
our laboratory and will be reported in the future. 
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Table legends 
 
Table 1. The IC50 and SI values of the total extracts and fractions of T. subcordata on 
Ovcar-8, A2780, and normal human OSE cells (the data are expressed as mean ± SEM 
(n=3).  
 
Sample and SI  
IC
50
 (µg/ml) 
Ovcar-8 A2780 OSE 
TSS 4.2 ± 1.1 2.6 ± 1.2 ND 
TSS1 
SI for TSS1 
  2.4 ± 0.5 
8.2  
2.1 ± 0.9 
9.5 
20 ± 1.3 
- 
TSS2 53 ± 3.0 39 ± 2.4 ND 
TSS3 
SI for SS3 
6.0 ±  2.1 
1.4 
3.5 ± 1.1 
2.4 
8.2 ± 1.1   
- 
 
Selective index (SI) is defined as the ratio of IC50 in OSE cells to that in the cancer 
cells. ND represents not determined. 
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Table 2. The IC50 and SI values of the BBIQ alkaloids of T. subcordata on Ovcar-8, 
A2780, Igrov-1 and Ovcar-4 cells (the data are expressed as mean ± SEM (n=3).  
 
Compound and SI 
IC
50
 (µM) 
Ovcar-8 A2780   Igrov-1             Ovcar-4  
Cycleanine 10 ± 0.6 7.6 ± 0.7   14 ± 1.0       7.2 ± 0.4  
SI for cycleanine 3.4 4.6   2.6                 4.8 
Tetrandrine    12 ± 1.4  7.7 ± 0.2 6.9 ± 0.6         9.3 ± 0.4 
Paclitaxel 5.2 nM  4.6 nM  ND                  8.7 nM 
 
IC50 of cycleanine on normal human OSE cells was determined as 35 ± 1.0 µM. 
Paclitaxel served as positive control. ND represents not determined. 
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Fig. Legends 
Fig. 1.  Cytotoxicity of extracts and alkaloids from T. subcordata. Concentration vs 
response curves of total alkaloid fraction (TSS1) from T. subcordata (A), and isolated 
cycleanine (B) on Ovcar-8 ovarian cancer cell line. The mean values of their IC
50
 are 
expressed as mean ± SEM (n = 3). Cell viability tests for A2780, Ovcar-8, Igrov-1 and 
Ovcar-4 cell lines post-treatment with carboplatin, cycleanine and tetrandrine (20 µM) 
using countess automated cell counter (C). 
Fig. 2.  Enzymatic activities of caspase 3/7 after 48 h treatment of Ovcar-8 (A), A2780 
(B) and Igrov-1 (C) cells with medium, carboplatin, cycleanine, and tetrandrine (20 
μM). The caspase activity is expressed as fold increase relative to control cells (mean ± 
S.D., n = 3). The caspase activity was significantly increased following carboplatin, 
cycleanine and tetrandrine exposure compared to cells treated with medium (control) 
where indicated (one way ANOVA for group analysis, P<0.0001 for Ovcar-8 and 
Igrov-1 cells, and P=0.0044 for A2780 cell line; paired t-test relative to control, *, P 
<0.05; **, P <0.005; ***, P <0.0001).  
Fig. 3. Western blotting analysis of the PARP cleavage marker in Ovcar-8 cells after 
treatment with carboplatin, cycleanine and tetrandrine. GAPDH was used as a loading 
control (n = 3). Quantification showed that the treatment of carboplatin, cycleanine and 
tetrandrine led to 1.1-, 1.5- and 1.4-fold increase in PARP compared to control cells, 
respectively. Cycleanine and tetrandrine induced 1.1- and 1.3-fold increase in PARP-1 
cleavage compared to carboplatin, respectively. 
Fig. 4. Flow cytometry analysis of apoptotic effects of carboplatin, cycleanine, and 
terandrine on Ovcar-8 cells. The scattering dot plots indicating the percentage of live, 
early and late apoptotic cells under treatment of medium (control) (A), carboplatin (B), 
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cycleanine (C), and tetrandrine (D) (20 μM) for 48 hours by using Annexin V & PI 
assay. The percentages of the total apoptotic cells caused by carboplatin, cycleanine, 
and tetrandrine were compared (E) (one way ANOVA for group analysis, P<0.0001; 
paired t-test relative to control, *, P <0.05; **, P <0.005).  
  
Fig. 5.  The effects of carboplatin, cycleanine, and tetrandrine on the cell cycle. Flow 
cytometry analysis of the DNA content in Ovcar-8 cells exposed to medium (control) 
(A), carboplatin (B), cycleanine (C), and tetrandrine (D) (20 μM) for 48 hours by using 
only PI staining. The percentage of carboplatin, cycleanine, and tetrandrine-treated cells 
in subG1 phase of the cell cycle was significantly increased compared to cells exposed 
to medium alone. 
